GAMMA Investing LLC Boosts Holdings in Inari Medical, Inc. (NASDAQ:NARI)

GAMMA Investing LLC raised its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 66.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,963 shares of the company’s stock after purchasing an additional 786 shares during the quarter. GAMMA Investing LLC’s holdings in Inari Medical were worth $100,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. KBC Group NV boosted its holdings in Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after purchasing an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its holdings in Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after purchasing an additional 522 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Inari Medical in the second quarter valued at $104,000. Quest Partners LLC boosted its holdings in Inari Medical by 31,257.1% in the second quarter. Quest Partners LLC now owns 2,195 shares of the company’s stock valued at $106,000 after purchasing an additional 2,188 shares during the last quarter. Finally, Covestor Ltd boosted its holdings in Inari Medical by 63.5% in the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after purchasing an additional 926 shares during the last quarter. 90.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

NARI has been the topic of several recent research reports. Truist Financial upped their price target on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. Stifel Nicolaus began coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 target price on the stock. BTIG Research reissued a “neutral” rating on shares of Inari Medical in a research note on Wednesday. Robert W. Baird reissued a “neutral” rating and set a $80.00 target price (down from $81.00) on shares of Inari Medical in a research note on Tuesday. Finally, Piper Sandler increased their target price on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday. Twelve analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $68.00.

Inari Medical Trading Down 0.0 %

Shares of Inari Medical stock opened at $79.29 on Friday. The firm has a market capitalization of $4.64 billion, a PE ratio of -58.73 and a beta of 0.97. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $79.69. The firm’s 50-day moving average price is $54.11 and its 200 day moving average price is $49.35.

Insiders Place Their Bets

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $60.47, for a total value of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares of the company’s stock, valued at $14,451,543.89. This trade represents a 45.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total transaction of $165,870.00. Following the completion of the transaction, the chief executive officer now directly owns 439,310 shares in the company, valued at $24,289,449.90. This trade represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 406,000 shares of company stock valued at $22,621,870 in the last ninety days. 10.60% of the stock is currently owned by corporate insiders.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.